| Literature DB >> 30515599 |
Thomas M Atkinson1, Bryce B Reeve2, Amylou C Dueck3, Antonia V Bennett4, Tito R Mendoza5, Lauren J Rogak6, Ethan Basch6,4, Yuelin Li6.
Abstract
BACKGROUND: Traditional concordance metrics have shortcomings based on dataset characteristics (e.g., multiple attributes rated, missing data); therefore it is necessary to explore supplemental approaches to quantifying agreement between independent assessments. The purpose of this methodological paper is to apply an Item Response Theory (IRT) -based framework to an existing dataset that included unidimensional clinician and multiple attribute patient ratings of symptomatic adverse events (AEs), and explore the utility of this method in patient-reported outcome (PRO) and health-related quality of life (HRQOL) research.Entities:
Keywords: Clinician-patient agreement; Item response theory; Neoplasms; Patient-reported outcomes
Year: 2018 PMID: 30515599 PMCID: PMC6279753 DOI: 10.1186/s41687-018-0086-x
Source DB: PubMed Journal: J Patient Rep Outcomes ISSN: 2509-8020
Fig. 1Graded Response Model tracelines depicting two orthopedic surgeons’ responses in classifying hip fracture severity. Note: Posterior mean severity locations of three patients are superimposed. Plot recreated using published data [6]
Example of data entry structure
| PRO-CTCAE | CTCAE | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Patient ID | Frequency | Severity | Interference | Clinic1 | Clinic2 | Clinic3 | Clinic4 | Clinic43 | Clinic44 | Clinic45 |
| 001 | 1 | 1 | 1 | 0 | N/A | N/A | N/A | N/A | N/A | N/A |
| 002 | 0 | – | – | N/A | 1 | N/A | N/A | N/A | N/A | N/A |
| 003 | 2 | 1 | 2 | N/A | N/A | 1 | N/A | N/A | N/A | N/A |
| 004 | 1 | 2 | 0 | N/A | N/A | 1 | N/A | N/A | N/A | N/A |
| 005 | 0 | – | – | N/A | N/A | 0 | N/A | N/A | N/A | N/A |
| 006 | 1 | 2 | 3 | N/A | N/A | N/A | 2 | N/A | N/A | N/A |
| 007 | 2 | 1 | 0 | N/A | N/A | N/A | 0 | N/A | N/A | N/A |
| 008 | 1 | 1 | 3 | N/A | N/A | N/A | 1 | N/A | N/A | N/A |
| 935 | 2 | 1 | 1 | N/A | N/A | N/A | N/A | 1 | N/A | N/A |
| 936 | 0 | – | – | N/A | N/A | N/A | N/A | 0 | N/A | N/A |
| 937 | 2 | 2 | 2 | N/A | N/A | N/A | N/A | 2 | N/A | N/A |
| 938 | 1 | 1 | 2 | N/A | N/A | N/A | N/A | 1 | N/A | N/A |
| 939 | 2 | 1 | 0 | N/A | N/A | N/A | N/A | N/A | 2 | N/A |
| 940 | 2 | 2 | 3 | N/A | N/A | N/A | N/A | N/A | N/A | 1 |
Note: CTCAE indicates Common Terminology Criteria for Adverse Events, PRO-CTCAE indicates Patient-Reported Outcomes version of the Common Terminology for Adverse Events. Clinic# indicates which of the 45 clinics (grouping clinicians within the same clinic) provided the CTCAE grades. N/A indicates data was not collected for a given patient in a given clinic. -- indicates PRO-CTCAE data was not captured for the severity and interference attributes for a given adverse event due to the frequency attribute being assigned a zero (never) rating
Patient characteristics (N = 940)
| Characteristic | No. of Patients ( | % | |
|---|---|---|---|
| Age range | 19–91 | ||
| Mean, years (±SD) | 58.26 | ||
| Female | 539 | 57.3 | |
| ECOG Performance Status | |||
| Median | 1.00 | ||
| Disease | |||
| Breast | 260 | 27.7 | |
| Lung/Head/Neck | 329 | 35.0 | |
| Gastrointestinal | 95 | 10.1 | |
| Genitourinary/Gynecologic | 172 | 18.3 | |
| Hematological | 47 | 5.0 | |
| Other/Unknown | 37 | 3.9 | |
| Race | |||
| White | 675 | 71.8 | |
| Black or African American | 203 | 21.6 | |
| Native Hawaiian/Pacific Islander | 5 | 0.5 | |
| Asian | 42 | 4.5 | |
| Native American/Pacific Islander | 2 | 0.2 | |
| Multiple Reported | 13 | 1.4 | |
Note: ECOG indicates Eastern Cooperative Oncology Group
Distribution of Raw CTCAE Ratings when PRO-CTCAE Pain ratings all 1, 2, or 3 (n = 83)
| CTCAE Pain Grade | |||||
|---|---|---|---|---|---|
| PRO-CTCAE Pain Rating | |||||
| Frequency | Severity | Interference | 1 | 2 | 3 |
| ‘rarely’ | ‘mild’ | ‘a little bit’ | 21 | 3 | 0 |
| ‘occasionally’ | ‘moderate’ | ‘somewhat’ | 27 | 8 | 0 |
| ‘frequent’ | ‘severe’ | ‘quite a bit’ | 9 | 10 | 5 |
Note: This example represents respondents for which CTCAE and PRO-CTCAE pain was captured, and where frequency, severity and interference were rated as all 1, 2, or 3 by patients
Example of cross-tabulation of CTCAE pain grades and PRO-CTCAE pain severity ratings (n = 525)
| CTCAE Pain grade | ||||||
|---|---|---|---|---|---|---|
| PRO-CTCAE Pain severity | 0 | 1 | 2 | 3 | Total | |
| ‘none’ | 0 | 2 | 2 | 1 | 0 | 5 |
| ‘mild’ | 1 | 112 | 85 | 13 | 0 | 210 |
| ‘moderate’ | 2 | 56 | 92 | 32 | 3 | 183 |
| ‘severe’ | 3 | 16 | 33 | 29 | 13 | 91 |
| ‘very severe’ | 4 | 4 | 5 | 21 | 6 | 36 |
| Total | 190 | 217 | 96 | 22 | 525 | |
Note: This sample size represents respondents in whom both CTCAE and PRO-CTCAE pain ratings were captured
Means, standard deviations, and traditional concordance metrics for patient adverse events
| Mean (Standard Deviation) | Concordance Metric | ||||||
|---|---|---|---|---|---|---|---|
| PRO-CTCAE | CTCAE | ||||||
| Adverse Event | Frequency | Severity | Interference | Grade | Weighted κ | Spearman | % |
| Anxiety | 1.18 (1.08) | 1.55 (0.79) | 1.07 (1.13) | 0.48 (0.66) | 0.05 | 0.36* | 0.28 |
| Dyspnea | ** | 0.69 (0.93) | 1.32 (1.13) | 0.34 (0.60) | 0.41* | 0.58* | 0.64 |
| Edema | 0.57 (1.10) | 1.68 (0.88) | 1.17 (1.28) | 0.16 (0.41) | 0.07 | 0.13 | 0.22 |
| Fatigue | ** | 1.68 (1.07) | 1.80 (1.14) | 0.98 (0.77) | 0.25* | 0.48* | 0.37 |
| Feeling Nothing/Cheer Up | 0.67 (0.96) | 1.43 (0.83) | 1.17 (1.05) | 0.30 (0.55) | 0.09 | 0.30* | 0.25 |
| Headache | 0.74 (0.95) | 1.46 (0.71) | 0.96 (1.00) | 0.20 (0.46) | 0.05 | 0.21* | 0.19 |
| Insomnia | ** | 1.13 (1.12) | 1.43 (1.12) | 0.51 (0.71) | 0.29* | 0.50* | 0.48 |
| Mucositis | ** | 0.42 (0.84) | 1.09 (1.19) | 0.16 (0.49) | 0.35* | 0.47* | 0.77 |
| Nausea | 0.86 (1.07) | 1.55 (0.86) | ** | 0.33 (0.56) | 0.09 | 0.31* | 0.28 |
| Pain | 1.35 (1.29) | 1.89 (0.95) | 1.62 (1.25) | 0.61 (0.79) | 0.15 | 0.44* | 0.25 |
| Problems w/Concentration | ** | 0.71 (0.90) | 1.24 (0.98) | 0.34 (0.54) | 0.30* | 0.43* | 0.58 |
| Sad/Unhappy Feelings | 1.14 (0.99) | 1.42 (0.76) | 0.94 (1.04) | 0.30 (0.55) | 0.08 | 0.39* | 0.21 |
| Vomiting | 0.29 (0.71) | 1.51 (0.94) | ** | 0.10 (0.36) | 0.10 | 0.34* | 0.25 |
Note: Concordance was calculated between PRO-CTCAE severity and CTCAE ratings, ** indicates attribute not assessed, * indicates significant p < 0.01
Bayesian Graded Response Model Estimates for Pain
| α parameter | κ parameter | |||||||
|---|---|---|---|---|---|---|---|---|
| Frequency | Severity | Interference | 1–4 vs. 0 | 2–4 vs. 0–1 | 3–4 vs. 0–2 | 4 vs. 0–3 | ||
| Patient | 5.04 | 5.69 | 4.33 | Frequency | −2.58 | 0.41 | 3.99 | 6.98 |
| Severity | −6.46 | 1.21 | 5.48 | 9.10 | ||||
| Interference | −0.92 | 1.78 | 4.25 | 6.70 | ||||
| Clinic 1 | 1.88 | – | – | 0.48 | 2.12 | 2.69 | 5.29 | |
| Clinic 2 | 2.31 | – | – | −0.32 | 2.06 | 3.84 | 5.50 | |
| Clinic 3 | 2.09 | – | – | −0.38 | 2.09 | 4.25 | 5.94 | |
| Clinic 4 | 1.16 | – | – | −1.39 | 1.20 | 2.34 | 4.58 | |
| Clinic 5 | 2.38 | – | – | −0.47 | 2.12 | 3.32 | 5.92 | |
| Clinic 6 | 1.54 | – | – | −0.54 | 1.95 | 3.85 | 4.95 | |
| Clinic 7 | 1.31 | – | – | −0.50 | 2.03 | 4.10 | 5.17 | |
| Clinic 8 | 2.02 | – | – | −0.47 | 0.57 | 3.95 | 5.03 | |
| Clinic 9 | 1.94 | – | – | −0.24 | 2.05 | 3.31 | 5.04 | |
| Clinic 10 | 1.14 | – | – | −0.21 | 1.60 | 3.30 | 4.48 | |
| Clinic 11 | 2.23 | – | – | 0.10 | 1.96 | 4.83 | 5.79 | |
| Clinic 12 | 1.92 | – | – | −0.06 | 1.62 | 4.13 | 5.19 | |
| Clinic 13 | 2.44 | – | – | 0.05 | 1.65 | 3.72 | 4.83 | |
| Clinic 14 | 2.14 | – | – | −0.12 | 2.04 | 4.06 | 5.66 | |
| Clinic 15 | 1.11 | – | – | 0.26 | 2.16 | 2.94 | 4.20 | |
| Clinic 16 | 0.53 | – | – | 0.75 | 2.61 | 3.70 | 4.82 | |
| Clinic 17 | 1.27 | – | – | 0.28 | 1.81 | 4.03 | 5.62 | |
| Clinic 18 | 1.62 | – | – | 0.76 | 2.72 | 3.92 | 5.49 | |
| Clinic 19 | 1.93 | – | – | 0.18 | 3.24 | 5.16 | 6.08 | |
| Clinic 20 | 1.99 | – | – | −0.20 | 2.64 | 4.52 | 5.53 | |
| Clinic 21 | 2.88 | – | – | −1.20 | 1.42 | 2.33 | 4.83 | |
| Clinic 22 | 2.52 | – | – | 0.51 | 2.78 | 3.90 | 4.98 | |
| Clinic 23 | 1.95 | – | – | 0.50 | 2.35 | 4.76 | 5.74 | |
| Clinic 24 | 0.66 | – | – | −0.86 | 0.66 | 2.98 | 4.23 | |
| Clinic 25 | 1.12 | – | – | 0.61 | 1.94 | 3.50 | 5.11 | |
| Clinic 26 | 1.24 | – | – | −0.40 | 1.80 | 3.34 | 5.62 | |
Fig. 2Graded Response Model Estimates for Patients/Clinicians, and Difference between Patient and Clinicians for Two-Attribute Symptoms. Note: X-axis represents underlying distribution of AE in the population (θ parameter in the GRM); Y-axis represents the model estimated AE ratings. In the case of fatigue, θ represents severity and interference with daily activities
Fig. 3Graded Response Model Estimates for Patients/Clinicians, and Difference between Patient and Clinicians for Three-Attribute Symptoms. Note: X-axis represents underlying distribution of AE in the population (θ parameter in the GRM); Y-axis represents the model estimated AE ratings. In the case of pain, θ represents frequency, severity, and interference with daily activities